Jason Haas

CIK 1883821 · Chief Financial Officer · last filed 2026-06-15

Jason Haas is a Chief Financial Officer who has filed 20 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for LGND, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$4.69M

Companies

3

Total Filings

20

Lifetime Open-Market Net

-$1.50M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LGND Director 11,442 $293.15 $3.35M -$1.65M 6 2026-06-15
ODTX Chief Financial Officer 62,908 $21.17 $1.33M $20.0K 1 2026-05-11
Syros Pharmaceuticals, Inc. (SYRS) Delisted Chief Financial Officer 0 $0.00 $0 $132.3K 10 2024-11-20

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-15 LGND Mixed −2,461 -$1.45M EDGAR
2026-06-12 LGND Notice (144) −6,461 -$1.65M EDGAR
2026-06-09 LGND Grant (A) +836 $0 EDGAR
2026-05-11 ODTX Buy (P) +1,000 $20.0K EDGAR
2025-06-10 LGND Grant (A) +1,209 $0 EDGAR
2024-11-20 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −137,803 -$29.0K EDGAR
2024-11-18 Notice (144) −37,803 -$8.7K EDGAR
2024-11-18 Notice (144) −100,000 -$20.3K EDGAR
2024-11-04 Syros Pharmaceuticals, Inc. (SYRS) Delisted Mixed +13,251 -$11.8K EDGAR
2024-09-12 Syros Pharmaceuticals, Inc. (SYRS) Delisted Buy (P) +100,000 $161.2K EDGAR
Showing 110 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.